The most widely studied targeted therapies for the third- and further-line treatment of NSCLC are EGFR inhibitors: gefitinib, erlotinib, cetuximab and afatinib (Table 3). The most important predictive ...
Please provide your email address to receive an email when new articles are posted on . Patients with PBC and advanced fibrosis are not offered second-line therapy despite having “most to gain by ...
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...
BERLIN — Ulcerative colitis (UC) patients who fail on first-line therapy appear to have better outcomes with vedolizumab (Entyvio) than with infliximab, suggests EFFICACI, the first trial directly ...
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database Between April 2019 ...
Clinical cure and no disease recurrence within 60 days without additional treatment was observed in 66.7% of 51 patients receiving FMT vs 61.2% of 49 patients receiving vancomycin. HealthDay News — ...
Advanced gastroesophageal adenocarcinoma (GEA) with HER2 positivity has long presented significant treatment challenges, with first-line therapies offering limited survival benefits despite advances ...
Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results